A Nigerian firm manufactures rapid diagnostic tests locally through the WHO tech transfer

In a landmark achievement for local manufacturing, a Nigerian health technology company, Codix Bio, has been selected to produce rapid diagnostic tests (RDTs) domestically. This initiative is part of a technology transfer program led by the WHO and the Medicines Patent Pool. The agreement allows the Nigerian firm to manufacture high-quality tests for diseases like HIV, malaria, and syphilis using world-class technology that was previously only available from foreign suppliers.

This is a significant step toward health independence for Nigeria and the broader African continent. By producing these essential diagnostic tools locally, the country can reduce its reliance on expensive imports and ensure a steady supply during health emergencies. The project aims to make life-saving diagnostics more affordable and accessible to low-income populations. It serves as a model for how international partnerships can empower local industries to solve regional health challenges from within.

Read the original article at: https://www.who.int/news/item/09-05-2025-who-and-medicines-patent-pool-announce-sublicensing-agreement-for-rapid-diagnostic-test-technology


Follow us on Instagram, Twitter, and Facebook to stay up to date with what's new in healthcare all around the world.

 

Comments

Popular posts from this blog

Ghana's "Lightwave" system creates paperless hospitals, reducing wait times and digitizing patient records

Africa Health Insights: 20th November - 26th November' 2025

NGO urges sustainable emergency-operation centres in Nigeria’s PHCs